Home >> Tag Archives: Horizon Discovery Group—

Tag Archives: Horizon Discovery Group—

Horizon, Roche team up to develop IHC assays

Dec. 20, 2017—Horizon Discovery Group announced that it has entered into an agreement with Roche Diagnostics to assist in the development of immunohistochemistry assays. Under the terms of the agreement, Horizon will develop and provide reference standard material expressing neurotrophic tropomyosin receptor kinase fusion biomarkers. NTRK gene rearrangements have emerged recently as promising targets for cancer therapy, and a number ...

Read More »

Horizon license for gene editing platform

July 13, 2017—Horizon Discovery Group has completed licensing agreements with all joint patent holders to provide exclusive worldwide rights to a novel transposon-based gene editing technology platform. The license broadens Horizon’s gene editing capabilities, with immediate applications in biomanufacturing, diagnostics, and cell therapy. For diagnostics, Horizon can use the technology to efficiently develop reference standards for assays designed to measure ...

Read More »

Fulcrum to use Horizon’s CRISPR platform

Sept. 16, 2016—Horizon Discovery Group announced a collaboration with Fulcrum Therapeutics to use Horizon’s CRISPR-based screening platform to identify novel targets for regulating gene expression. The program will initially focus on genetic diseases where no effective treatment options exist. Horizon’s CRISPR-based screening platform, sophisticated bioinformatics, and cell line libraries aim to provide a novel and highly efficient way to examine ...

Read More »

Horizon, Ventana partner on IHC reference standards

Sept. 14, 2016—Horizon Discovery Group has entered into a co-development and commercialization agreement with Ventana Medical Systems, a member of the Roche Group. The agreement covers the development, manufacture, and commercialization of cell-line derivative materials for use as IHC reference standards in cancer tissue diagnostics to support the development and validation of IHC assays. Ventana provides products used in clinical ...

Read More »

Horizon takes license for Wistar melanoma models

Aug. 26, 2016—Horizon Discovery Group and the Wistar Institute announced that Horizon has taken an exclusive license to 153 of Wistar’s melanoma patient-derived xenograft models. PDX models allow researchers to examine how human tumors grow and respond to drugs in a living organism. Horizon distribution of the Wistar melanoma PDX collection will allow scientists worldwide to investigate the efficacy and ...

Read More »

Qiagen adds Horizon QC to NGS system

June 6, 2016—Horizon Discovery Group announced that Qiagen will be offering an extensive package of quality control data, generated through the application of Horizon’s Reference Standards, with its GeneReader NGS System. As part of the project, Qiagen thoroughly validated its platform using Horizon’s molecular reference standards. By incorporating this data set into the GeneReader NGS System workflows, Qiagen is able ...

Read More »

Horizon enters immuno-oncology venture

March 22, 2016—Horizon Discovery Group has formed an immuno-oncology joint venture with Centauri Therapeutics, a U.K.-based biotechnology company focused on the discovery and development of novel molecules targeting life-threatening infectious diseases. This transaction represents part of Horizon’s previously outlined strategy to invest more than $14 million to identify the next generation of molecular and cellular cancer therapeutics. The newly formed ...

Read More »
X